On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Divis Laboratories has increased 25.01% to Rs 2319 crore. Operating profit margin has jumped from 26.36% to 32.04%, leading to 51.94% rise in operating profit to Rs 743.00 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 41.35% to 42.22%. Employee cost decreased from 13.96% to 12.28%. Other expenses fell from 19.22% to 14.76%. Other income fell 13.68% to Rs 82 crore. PBIDT rose 41.27% to Rs 825 crore. Provision for interest remained nil. PBDT rose 41.27% to Rs 825 crore. Provision for depreciation rose 4.21% to Rs 99 crore. Profit before tax grew 48.47% to Rs 726.00 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 137 crore, compared to Rs 131 crore. Effective tax rate was 18.87% compared to 26.79%. Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 64.53% to Rs 589.00 crore. Promoters’ stake was 51.89% as of 31 December 2024 ,compared to 51.92% as of 31 December 2023 .
For year-to-date (YTD) results analysis.
Net sales (including other operating income) of Divis Laboratories has increased 22.25% to Rs 6775 crore. Operating profit margin has jumped from 26.56% to 30.72%, leading to 41.37% rise in operating profit to Rs 2,081.00 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 41.32% to 41.76%. Employee cost decreased from 14.11% to 12.90%. Other expenses fell from 18.52% to 15.27%. Other income rose 1.91% to Rs 267 crore. PBIDT rose 35.41% to Rs 2348 crore. PBDT rose 35.43% to Rs 2347 crore. Provision for depreciation rose 4.24% to Rs 295 crore. Profit before tax grew 41.52% to Rs 2,052.00 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 523 crore, compared to Rs 388 crore. Effective tax rate was 25.49% compared to 26.76%.Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 43.97% to Rs 1,529.00 crore. Promoters’ stake was 51.89% as of 31 December 2024 ,compared to 51.92% as of 31 December 2023 .
Full year results analysis.
Net sales (including other operating income) of Divis Laboratories has increased 1% to Rs 7845 crore. Operating profit margin has declined from 30.49% to 28.11%, leading to 6.88% decline in operating profit to Rs 2,205.00 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 38.84% to 40.63%. Purchase of finished goods cost fell from 0.28% to 0.08%. Employee cost increased from 12.59% to 13.75%. Other expenses rose from 17.70% to 17.81%. Other income fell 1.74% to Rs 339 crore. PBIDT fell 6.23% to Rs 2544 crore. Provision for interest rose 200% to Rs 3 crore. Loan funds declined from Rs 4.00 crore as of 31 March 2023 to Rs 3.00 crore as of 31 March 2024. Inventories rose to Rs 3,184.00 crore as of 31 March 2024 from Rs 3,000.00 crore as of 31 March 2023. Sundry debtors were higher at Rs 2,156.00 crore as of 31 March 2024 compared to Rs 1,793.00 crore as of 31 March 2023. Cash and bank balance declined from Rs 4,214.00 crore as of 31 March 2023 to Rs 3,980.00 crore as of 31 March 2024. Investments rose to Rs 82.00 crore as of 31 March 2024 from Rs 77.00 crore as of 31 March 2023 . PBDT fell 6.31% to Rs 2541 crore. Provision for depreciation rose 10.20% to Rs 378 crore. Fixed assets increased to Rs 5,513.00 crore as of 31 March 2024 from Rs 4,929.00 crore as of 31 March 2023. Intangible assets declined from Rs 5.00 crore to Rs 4.00 crore. Profit before tax down 8.70% to Rs 2,163.00 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 563 crore, compared to Rs 545 crore. Effective tax rate was 26.03% compared to 23.01%. Minority interest was nil in both the periods. Net profit attributable to owners of the company decreased 12.28% to Rs 1,600.00 crore. Equity capital stood at Rs 53.00 crore as of 31 March 2024 to Rs 53.00 crore as of 31 March 2023. Per share face Value remained same at Rs 2.00. Promoters’ stake was 51.92% as of 31 March 2024 ,compared to 51.94% as of 31 March 2023 . Cash flow from operating activities decreased to Rs 1,261.00 crore for year ended March 2024 from Rs 2,459.00 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 1,003.00 crore, compared to Rs 473.00 crore during the year ended March 2023. Other highlights
In 9M FY25, the company has capitalized
assets of Rs 557 crore. Of this, capitalization for Kakinada Project is Rs 418
crore.
A part of the Kakinada Project (Unit-III)
commenced commercial operations from 1 January 2025. The rest of Kakinada
project is being implemented and is expected to be operational in about 6
months.
| Divis Laboratories : Consolidated Results | | | Quarter ended | Year to Date | Year ended |
|---|
| Particulars | 202412 | 202312 | Var.(%) | 202412 | 202312 | Var.(%) | 202403 | 202303 | Var.(%) |
|---|
| Net Sales (including other operating income) | 2,319.00 | 1,855.00 | 25.01 | 6,775.00 | 5,542.00 | 22.25 | 7,845.00 | 7,767.00 | 1.00 | | OPM (%) | 32.04 | 26.36 | 568 bps | 30.72 | 26.56 | 416 bps | 28.11 | 30.49 | -238 bps | | OP | 743.00 | 489.00 | 51.94 | 2,081.00 | 1,472.00 | 41.37 | 2,205.00 | 2,368.00 | -6.88 | | Other Inc. | 82.00 | 95.00 | -13.68 | 267.00 | 262.00 | 1.91 | 339.00 | 345.00 | -1.74 | | PBIDT | 825.00 | 584.00 | 41.27 | 2,348.00 | 1,734.00 | 35.41 | 2,544.00 | 2,713.00 | -6.23 | | Interest | 0 | 0 | - | 1.00 | 1.00 | 0 | 3.00 | 1.00 | 200.00 | | PBDT | 825.00 | 584.00 | 41.27 | 2,347.00 | 1,733.00 | 35.43 | 2,541.00 | 2,712.00 | -6.31 | | Depreciation | 99 | 95 | 4.21 | 295 | 283 | 4.24 | 378 | 343 | 10.20 | | PBT | 726.00 | 489.00 | 48.47 | 2052 | 1450 | 41.52 | 2163 | 2369 | -8.70 | | Share of Profit/(Loss) from Associates | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | PBT before EO | 726 | 489 | 48.47 | 2052 | 1450 | 41.52 | 2163 | 2369 | -8.70 | | EO Income | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | PBT after EO | 726 | 489 | 48.47 | 2052 | 1450 | 41.52 | 2163 | 2369 | -8.70 | | Taxation | 137 | 131 | 4.58 | 523 | 388 | 34.79 | 563 | 545 | 3.30 | | PAT | 589 | 358 | 64.53 | 1529 | 1062 | 43.97 | 1600 | 1824 | -12.28 | | Minority Interest (MI) | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit | 589 | 358 | 64.53 | 1529 | 1062 | 43.97 | 1600 | 1824 | -12.28 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit after discontinued operations | 589 | 358 | 64.53 | 1529 | 1062 | 43.97 | 1600 | 1824 | -12.28 | | EPS (Rs)* | 22.19 | 13.49 | 64.53 | 57.60 | 40.00 | 43.97 | 60.27 | 68.71 | -12.28 | | | * EPS is on current equity of Rs 53.09 crore, Face value of Rs 2, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|